Abstract
Cutaneous squamous cell carcinoma (cSCC) exhibits overall favorable prognosis with most cases cured by surgical intervention. However, due to an annual incidence of nearly 1 million patients diagnosed, the estimated deaths attributed to cSCC approach or surpass those from melanoma. Management decisions for high-risk cSCC are complicated by the limited accuracy of current staging systems, highlighting a need for additional prognostic biomarkers. The objective of this study was to develop a gene expression profile (GEP) test that identifies patients at low or high risk for nodal or distant metastasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
